Viewing Study NCT01875367


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2026-02-26 @ 8:12 PM
Study NCT ID: NCT01875367
Status: COMPLETED
Last Update Posted: 2023-04-05
First Post: 2013-06-07
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
Sponsor: Spanish Breast Cancer Research Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Subcutaneous trastuzumab View
None Intravenous trastuzumab View
None HER2 positive View
None Advanced Breast Cancer View